174 related articles for article (PubMed ID: 24792966)
1. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.
Eigenbrod S; Trabold R; Brucker D; Erös C; Egensperger R; La Fougere C; Göbel W; Rühm A; Kretzschmar HA; Tonn JC; Herms J; Giese A; Kreth FW
Acta Neurochir (Wien); 2014 Aug; 156(8):1427-40. PubMed ID: 24792966
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
4. Detection of IDH1 mutations and the status of MGMT promoter on intraoperative fresh tissue section from frameless neuronavigation needle biopsy. Analysis on 17 patients with brain glial tumor ineligible for craniotomy and tumor resection.
Iaccarino I; Nicoli D; Serra S; Froio E; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F; Carinci F
Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):45-50. PubMed ID: 21781445
[TBL] [Abstract][Full Text] [Related]
5. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
6. Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas.
Gessler F; Baumgarten P; Bernstock JD; Harter P; Lescher S; Senft C; Seifert V; Marquardt G; Weise L
J Neurooncol; 2017 Jun; 133(2):399-407. PubMed ID: 28508327
[TBL] [Abstract][Full Text] [Related]
7. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
8. Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy of 25 patients with brain tumor.
Iaccarino C; Nicoli D; Serra S; Froio E; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F; Carinci F
Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):37-43. PubMed ID: 21781444
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
10. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
[TBL] [Abstract][Full Text] [Related]
11. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Ruiter M; Mehrkens JH; Kreth S; Tonn JC; Kretzschmar HA; Kreth FW
J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
[TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
14. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
15. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
[TBL] [Abstract][Full Text] [Related]
16. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
17. Progress in the application of molecular biomarkers in gliomas.
Wang J; Su HK; Zhao HF; Chen ZP; To SS
Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
20. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
